Credit Suisse AG lowered its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 0.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 141,255 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Credit Suisse AG owned approximately 0.20% of Ultragenyx Pharmaceutical worth $5,849,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. Signaturefd LLC lifted its stake in Ultragenyx Pharmaceutical by 151.0% in the third quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 361 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $27,000. Lazard Asset Management LLC raised its position in shares of Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 240 shares during the period. High Net Worth Advisory Group LLC raised its position in shares of Ultragenyx Pharmaceutical by 650.0% in the third quarter. High Net Worth Advisory Group LLC now owns 1,500 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 1,300 shares during the period. Finally, Echo Street Capital Management LLC bought a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at about $234,000. Institutional investors and hedge funds own 93.17% of the company’s stock.
Insider Activity
In other news, CAO Theodore Alan Huizenga sold 2,031 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The shares were sold at an average price of $43.96, for a total value of $89,282.76. Following the sale, the chief accounting officer now directly owns 16,197 shares in the company, valued at approximately $712,020.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 6.70% of the stock is currently owned by corporate insiders.
Ultragenyx Pharmaceutical Stock Down 1.6 %
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last posted its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($2.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.03) by ($0.13). Ultragenyx Pharmaceutical had a negative net margin of 194.71% and a negative return on equity of 110.15%. The company had revenue of $103.35 million during the quarter, compared to analyst estimates of $105.11 million. During the same quarter in the previous year, the business posted ($1.79) earnings per share. The company’s revenue for the quarter was up 23.9% on a year-over-year basis. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.52 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the stock. SVB Leerink dropped their price objective on shares of Ultragenyx Pharmaceutical from $115.00 to $108.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. Cowen dropped their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $65.00 in a research report on Thursday, November 3rd. Robert W. Baird increased their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an “outperform” rating in a research report on Friday, February 17th. HC Wainwright reaffirmed a “buy” rating and set a $82.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 30th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $90.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 18th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $89.47.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII.
Read More
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
